Drug Profile


Alternative Names: SP-02; SP-02L; Zinapar; ZIO-101

Latest Information Update: 07 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Texas A&M University; University of Texas M. D. Anderson Cancer Center
  • Developer Solasia Pharma; ZIOPHARM Oncology
  • Class Antineoplastics; Arsenicals; Small molecules
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Peripheral T-cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Peripheral T-cell lymphoma
  • Phase I Solid tumours
  • No development reported Liver cancer; Lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma

Most Recent Events

  • 01 Mar 2016 Phase-II clinical trials in Peripheral T-cell lymphoma (Second-line therapy or greater, Monotherapy) in Japan (IV) (NCT02653976)
  • 27 Jan 2016 Solasia Pharma plans a phase II trial for Peripheral T-cell lymphoma (Monotherapy, Second-line therapy or greater) in Hong Kong, Japan, South Korea and Taiwan (NCT02653976)
  • 28 Jul 2015 No recent reports of development identified - Phase-I for Lymphoma (Late-stage disease) in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top